Astellas Venture Management

What Astellas Venture Management does

Astellas Venture Management (AVM) is the wholly-owned corporate venture capital subsidiary of Astellas Pharma Inc., a major Japanese pharmaceutical company headquartered in Tokyo. Founded around 2003 and based at 480 Forbes Blvd in South San Francisco, California, AVM has operated for over 20 years making equity investments in privately owned, early-stage biotechnology companies. Its investment focus is on preclinical-stage therapeutic programs and platform technologies whose science either enhances Astellas Pharma's existing R&D pipeline or catalyzes new directions in discovery research.

AVM's core offering to portfolio companies is strategic equity capital paired with what it calls a 'Pharma View' — pharmaceutical industry expertise drawn from long-standing experience within Astellas — and an explicit liaison function into Astellas Pharma for potential future collaborations. The active portfolio spans multiple therapeutic modalities including protein degradation (Avilar Therapeutics, Casma Therapeutics, Pallando Therapeutics, PhoreMost, ResNovas), cell therapy (Shinobi Therapeutics, Catamaran Bio, Cellular Intelligence), gene therapy and optogenetics (Restore Vision, Syntax Bio), RNA-based therapeutics (Orna Therapeutics, Turn Biotechnologies), bispecific antibody-drug conjugates (DEM BioPharma, Sidewinder Therapeutics), and DNA mismatch repair-based discovery (NeoPhore). Notable former investments include Bicycle Therapeutics (IPO exit) and eFFECTOR Therapeutics (SPAC merger). AVM also operates the annual Astellas Future Innovator Prize with MBC BioLabs as a recurring deal-sourcing and ecosystem program.

AVM generates returns through equity appreciation in its portfolio companies and via potential licensing or collaboration transactions between portfolio companies and Astellas Pharma; it does not earn commercial product revenue. Its capital is sourced from its parent, and its small investment team (approximately 5–9 professionals) is drawn almost entirely from Astellas Pharma's research, clinical pharmacology, and business development functions, embedding pharma R&D judgment directly into deal selection.

Name

Astellas Venture Management

Legal name

Astellas Venture Management LLC

Website

https://astellasventure.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

1–10 employees

Short description

Astellas Venture Management is Astellas Pharma's corporate venture capital arm, making equity investments in preclinical-stage biotech companies developing therapeutic programs and platform technologies aligned with Astellas's R&D pipeline, while providing pharma expertise and collaboration pathways.

Ownership category

akta.pro rank

Product category

Venture capital / biotech strategic investing

NAICS

Portfolio Management and Investment Advice (523940), Portfolio Management and Investment Advice (52394)

SIC

Investment Advice (6282)

akta.pro primary industry

Corporate Development & Strategic Partnerships Advisory (JVs, Alliances, Carve-outs) (BPAHAOAG)

Keywords

• Venture capital investing
• Biotech equity investments
• Early-stage biotechnology
• Pharmaceutical venture funding
• Therapeutic platform investments

Headquarters

HQ city

Menlo Park

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Others

Revenue model

1. Equity Investment Returns: AVM generates returns through equity investments in early-stage biotech companies. As a strategic investor, they provide capital to private companies in exchange for equity stakes, with the goal of supporting pre-clinical cutting-edge science that can bring value to patients and potentially lead to future collaborations with Astellas Pharma or exit opportunities.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

AVM is the wholly-owned corporate venture capital organization within Astellas Pharma, making equity investments in privately owned, preclinical-stage biotechnology companies focused on therapeutic programs and platform technologies for drug discovery and development. Beyond capital, AVM provides portfolio companies with "Pharma View" insights derived from long-standing pharmaceutical industry experience and serves as a liaison to Astellas Pharma to facilitate dialogue around potential future collaborations.

Product overview

Astellas Venture Management (AVM) is a strategic venture capital organization that is a wholly-owned subsidiary of Astellas Pharma. Rather than offering a unified product or platform, AVM provides equity investments and strategic support to private, early-stage biotechnology companies developing therapeutic programs and platform technologies for drug discovery and development. AVM's portfolio spans multiple therapeutic modalities including protein degradation (Avilar Therapeutics, Casma Therapeutics, Pallando Therapeutics), cell therapy (Shinobi Therapeutics, Catamaran Bio, Cellular Intelligence), gene therapy (Restore Vision, Syntax Bio), RNA-based therapeutics (Orna Therapeutics, Turn Biotechnologies), antibody-drug conjugates (DEM BioPharma, Sidewinder Therapeutics), and various other innovative biotech platforms. The investment scope focuses on preclinical-stage companies with innovative therapeutic approaches aligned with Astellas Pharma's R&D strategy. Former investments include companies that have achieved exits through IPO (Bicycle Therapeutics), SPAC merger (eFFECTOR Therapeutics), and other undisclosed exits.

Differentiator

Problem solved

Functional benefit

Products and services

• Strategic equity investment in preclinical biotech companies Equity investment services provided to privately owned, preclinical-stage biotechnology companies developing therapeutic programs and platform technologies aligned with Astellas Pharma's R&D strategy. Targeted buyers are early-stage biotech firms seeking capital, pharma expertise, and a potential future collaboration pathway with Astellas Pharma.
• Pharma View strategic guidance for portfolio companies Strategic advisory support delivered to AVM portfolio companies, providing pharmaceutical industry expertise, R&D guidance, and a liaison channel to Astellas Pharma for potential future collaborations.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• MBC BioLabscoreStrategic or Co-development Partner · 29 October 2024Astellas and MBC BioLabs partner annually for the Astellas Future Innovator Prize program, supporting innovative early-stage biotech companies through the Diamond Ticket and prize awards.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Novartis Venture Fund: Strategic corporate venture capital arm of Novartis AG investing in early-stage life sciences companies worldwide. Co-invested with AVM in Sidewinder Therapeutics' $137M Series B and shares the same CVC model of backing preclinical-to-clinical biotech with the option of partnership with the parent pharma.
• Eli Lilly Ventures (Lilly Asia Ventures / Lilly Ventures): The corporate venture arm of Eli Lilly focused on equity investments in early-stage biotech. Operates the same strategic-investor CVC model as AVM, with capital deployments aligned to the parent company's therapeutic areas and modality pipeline strategy.
• M Ventures (Merck KGaA): Corporate venture capital arm of Merck KGaA that invests across biotech and life sciences. Comparable in structure to AVM as a wholly-owned CVC of a global pharma parent, deploying strategic capital into preclinical and early clinical-stage therapeutic platforms.
• Pfizer Ventures: The corporate venture capital arm of Pfizer Inc. investing in private biotech across multiple therapeutic areas and modalities. Direct structural analogue to AVM as a pharma-backed strategic equity investor targeting innovative early-stage drug discovery and platform technologies.
• Roche Venture Fund: Strategic venture arm of F. Hoffmann-La Roche focused on early-stage therapeutic investments. Operates the same strategic-CVC playbook as AVM, using equity investments and internal R&D collaboration pathways as the bridge to the parent company's pipeline.
• Sanofi Ventures: Corporate venture capital arm of Sanofi focused on early-stage biotech companies developing novel therapies. Highly comparable to AVM as a pharma CVC that deploys strategic equity capital with the optionality of follow-on partnership or acquisition by the parent.
• AbbVie Ventures: Corporate venture capital function of AbbVie, investing in early-stage biotechnology companies across immunology, oncology, neuroscience and other focus areas. Mirrors AVM's small-team, strategic-equity CVC structure.
• Takeda Ventures: Corporate venture arm of Takeda Pharmaceutical; like Astellas, Takeda is a Japanese-headquartered global pharma. Takeda Ventures closely matches AVM's profile as a Japanese-pharma-backed CVC making equity investments in early-stage biotech with strategic pipeline alignment.

Broad incumbents

• Johnson & Johnson Innovation - JJDC: One of the oldest and largest corporate venture capital arms in pharma, operating as a wholly-owned subsidiary of Johnson & Johnson. Although broader and larger than AVM, it is a comparable strategic-investor CVC model with deep pharma-parent backing and life sciences equity investing focus.
• BMS Ventures (Bristol Myers Squibb): Corporate venture capital function of Bristol Myers Squibb investing across therapeutic areas of strategic interest. Comparable as a large-pharma CVC with which AVM could co-invest, while operating at greater scale and broader mandate than AVM.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments71 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Astellas Venture Management